Leap Therapeutics Stock Price, News & Analysis (NASDAQ:LPTX)

$6.53 -0.01 (-0.15 %)
(As of 02/23/2018 07:30 AM ET)
Previous Close$6.54
Today's Range$6.37 - $6.65
52-Week Range$4.90 - $9.44
Volume48,300 shs
Average Volume66,036 shs
Market Capitalization$80.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Leap Therapeutics (NASDAQ:LPTX)

Leap Therapeutics logoLeap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer, cholangiocarcinoma, non-small cell lung cancer, and other tumor types, such as pancreatic, gastric, liver, head and neck, uterine, and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. .

Receive LPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LPTX
CUSIPN/A
Phone617-714-0360

Debt

Debt-to-Equity RatioN/A
Current Ratio2.75%
Quick Ratio2.75%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($10.67) per share
Price / Book-0.61

Profitability

Trailing EPSN/A
Net Income$-25,630,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-153.01%

Miscellaneous

Employees22
Outstanding Shares12,350,000

Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions

What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics Inc (NASDAQ:LPTX) announced its quarterly earnings data on Monday, November, 13th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by $0.12. View Leap Therapeutics' Earnings History.

Where is Leap Therapeutics' stock going? Where will Leap Therapeutics' stock price be in 2018?

3 analysts have issued 12-month price objectives for Leap Therapeutics' stock. Their forecasts range from $13.00 to $18.00. On average, they expect Leap Therapeutics' stock price to reach $15.50 in the next year. View Analyst Ratings for Leap Therapeutics.

Who are some of Leap Therapeutics' key competitors?

Who owns Leap Therapeutics stock?

Leap Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sabby Management LLC (0.72%). View Institutional Ownership Trends for Leap Therapeutics.

Who bought Leap Therapeutics stock? Who is buying Leap Therapeutics stock?

Leap Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for Leap Therapeutics.

How do I buy Leap Therapeutics stock?

Shares of Leap Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Leap Therapeutics' stock price today?

One share of Leap Therapeutics stock can currently be purchased for approximately $6.53.

How big of a company is Leap Therapeutics?

Leap Therapeutics has a market capitalization of $80.79 million. Leap Therapeutics employs 22 workers across the globe.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.


MarketBeat Community Rating for Leap Therapeutics (LPTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  77 (Thanks for Voting!)
Underperform Votes:  68 (Thanks for Voting!)
Total Votes:  145
MarketBeat's community ratings are surveys of what our community members think about Leap Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Leap Therapeutics (NASDAQ:LPTX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.50$15.50$15.50$15.50
Price Target Upside: 97.45% upside97.45% upside97.45% upside97.45% upside

Leap Therapeutics (NASDAQ:LPTX) Consensus Price Target History

Price Target History for Leap Therapeutics (NASDAQ:LPTX)

Leap Therapeutics (NASDAQ:LPTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/7/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$18.00N/AView Rating Details
3/1/2017CitigroupInitiated CoverageMarket PerformN/AView Rating Details
2/28/2017Raymond James FinancialInitiated CoverageOutperform -> Outperform$13.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Leap Therapeutics (NASDAQ:LPTX) Earnings History and Estimates Chart

Earnings by Quarter for Leap Therapeutics (NASDAQ:LPTX)

Leap Therapeutics (NASDAQ LPTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017($0.62)($0.73)ViewN/AView Earnings Details
8/11/2017Q2 2017($0.71)($0.74)ViewN/AView Earnings Details
5/12/2017Q1 2017($0.87)($1.39)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Leap Therapeutics (NASDAQ:LPTX) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.63 EPS
Next Year EPS Consensus Estimate: $-2.61 EPS

Dividends

Dividend History for Leap Therapeutics (NASDAQ:LPTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Leap Therapeutics (NASDAQ LPTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 58.40%
Institutional Ownership Percentage: 1.33%
Insider Trades by Quarter for Leap Therapeutics (NASDAQ:LPTX)

Leap Therapeutics (NASDAQ LPTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/14/2017Augustine LawlorCOOBuy1,057,769$6.09$6,441,813.21View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Leap Therapeutics (NASDAQ LPTX) News Headlines

Source:
DateHeadline
Zacks: Analysts Anticipate Leap Therapeutics Inc (LPTX) to Post -$0.77 Earnings Per ShareZacks: Analysts Anticipate Leap Therapeutics Inc (LPTX) to Post -$0.77 Earnings Per Share
www.americanbankingnews.com - February 22 at 3:14 AM
Analysts Anticipate Leap Therapeutics Inc (LPTX) to Post ($0.77) EPSAnalysts Anticipate Leap Therapeutics Inc (LPTX) to Post ($0.77) EPS
www.americanbankingnews.com - February 21 at 12:05 PM
Analysts Anticipate Leap Therapeutics Inc (LPTX) to Post ($0.77) Earnings Per ShareAnalysts Anticipate Leap Therapeutics Inc (LPTX) to Post ($0.77) Earnings Per Share
www.americanbankingnews.com - February 6 at 3:34 PM
Leap Therapeutics to Present at the 20th Annual BIO CEO & Investor ConferenceLeap Therapeutics to Present at the 20th Annual BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 9:32 AM
Zacks: Leap Therapeutics Inc (LPTX) Given $15.50 Average Price Target by BrokeragesZacks: Leap Therapeutics Inc (LPTX) Given $15.50 Average Price Target by Brokerages
www.americanbankingnews.com - February 2 at 7:24 PM
Leap Therapeutics (LPTX) and Aeglea Bio Therapeutics (AGLE) Head-To-Head ComparisonLeap Therapeutics (LPTX) and Aeglea Bio Therapeutics (AGLE) Head-To-Head Comparison
www.americanbankingnews.com - February 2 at 1:18 AM
Leap Therapeutics (LPTX) and The Competition Head to Head AnalysisLeap Therapeutics (LPTX) and The Competition Head to Head Analysis
www.americanbankingnews.com - January 24 at 1:38 PM
Leap Therapeutics (LPTX) Downgraded by Zacks Investment ResearchLeap Therapeutics (LPTX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 21 at 12:32 AM
 Brokerages Anticipate Leap Therapeutics Inc (LPTX) to Post -$0.77 EPS Brokerages Anticipate Leap Therapeutics Inc (LPTX) to Post -$0.77 EPS
www.americanbankingnews.com - January 19 at 5:28 AM
 Brokerages Set $15.50 Price Target for Leap Therapeutics Inc (LPTX) Brokerages Set $15.50 Price Target for Leap Therapeutics Inc (LPTX)
www.americanbankingnews.com - January 18 at 3:06 AM
Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors TrialLeap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial
finance.yahoo.com - January 16 at 9:23 AM
Head-To-Head Analysis: Leap Therapeutics (LPTX) & Its RivalsHead-To-Head Analysis: Leap Therapeutics (LPTX) & Its Rivals
www.americanbankingnews.com - January 15 at 9:16 PM
Leap Therapeutics (LPTX) Downgraded to "Hold" at Zacks Investment ResearchLeap Therapeutics (LPTX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 14 at 7:27 PM
 Leap Therapeutics Inc (LPTX) Given Average Rating of "Buy" by Brokerages Leap Therapeutics Inc (LPTX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 14 at 3:38 PM
Leap Therapeutics (LPTX) Upgraded by Zacks Investment Research to "Buy"Leap Therapeutics (LPTX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - January 9 at 6:08 AM
Leap Therapeutics (LPTX) & The Competition Head to Head ReviewLeap Therapeutics (LPTX) & The Competition Head to Head Review
www.americanbankingnews.com - January 2 at 9:14 PM
Contrasting Leap Therapeutics (LPTX) & Its PeersContrasting Leap Therapeutics (LPTX) & Its Peers
www.americanbankingnews.com - December 31 at 3:28 AM
Zacks: Leap Therapeutics Inc (LPTX) Receives Consensus Recommendation of "Buy" from AnalystsZacks: Leap Therapeutics Inc (LPTX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 28 at 1:10 AM
Form DEF 14A LEAP THERAPEUTICS, INC. For: Jan 12Form DEF 14A LEAP THERAPEUTICS, INC. For: Jan 12
www.streetinsider.com - December 19 at 5:29 PM
Zacks: Brokerages Set $15.50 Price Target for Leap Therapeutics Inc (LPTX)Zacks: Brokerages Set $15.50 Price Target for Leap Therapeutics Inc (LPTX)
www.americanbankingnews.com - December 13 at 8:48 AM
Zacks: Leap Therapeutics, Inc. (LPTX) Given $15.50 Average Price Target by AnalystsZacks: Leap Therapeutics, Inc. (LPTX) Given $15.50 Average Price Target by Analysts
www.americanbankingnews.com - November 27 at 10:06 AM
Leap Therapeutics Announces $18 Million Private Placement OfferingLeap Therapeutics Announces $18 Million Private Placement Offering
finance.yahoo.com - November 17 at 2:10 PM
What’s Installed For Leap Therapeutics Inc (LPTX)?What’s Installed For Leap Therapeutics Inc (LPTX)?
finance.yahoo.com - November 17 at 2:10 PM
Leap Therapeutics, Inc. (LPTX) COO Purchases $6,441,813.21 in StockLeap Therapeutics, Inc. (LPTX) COO Purchases $6,441,813.21 in Stock
www.americanbankingnews.com - November 16 at 4:22 PM
Leap Therapeutics, Inc. (LPTX) Issues  Earnings Results, Misses Estimates By $0.11 EPSLeap Therapeutics, Inc. (LPTX) Issues Earnings Results, Misses Estimates By $0.11 EPS
www.americanbankingnews.com - November 14 at 11:24 AM
Leap Therapeutics Reports Third Quarter 2017 Financial Results and Announces First Patient Dosed with DKN-01 and KEYTRUDA® (pembrolizumab) in Esophagogastric Cancer TrialLeap Therapeutics Reports Third Quarter 2017 Financial Results and Announces First Patient Dosed with DKN-01 and KEYTRUDA® (pembrolizumab) in Esophagogastric Cancer Trial
finance.yahoo.com - November 13 at 5:12 PM
Zacks: Analysts Set $15.50 Price Target for Leap Therapeutics, Inc. (LPTX)Zacks: Analysts Set $15.50 Price Target for Leap Therapeutics, Inc. (LPTX)
www.americanbankingnews.com - November 12 at 7:38 PM
Leap Therapeutics (LPTX) versus Mast Therapeutics (SVRA) Head to Head AnalysisLeap Therapeutics (LPTX) versus Mast Therapeutics (SVRA) Head to Head Analysis
www.americanbankingnews.com - October 22 at 6:26 PM
Leap Therapeutics: An Undervalued And Underfollowed Immuno-Oncology CompanyLeap Therapeutics: An Undervalued And Underfollowed Immuno-Oncology Company
seekingalpha.com - September 11 at 10:52 PM
Leap Therapeutics Announces Collaboration With EORTC to Evaluate DKN-01 in Combination with PD-L1 Cancer Immunotherapy and Chemotherapy In Esophagogastric and Biliary Tract CancersLeap Therapeutics Announces Collaboration With EORTC to Evaluate DKN-01 in Combination with PD-L1 Cancer Immunotherapy and Chemotherapy In Esophagogastric and Biliary Tract Cancers
finance.yahoo.com - September 9 at 5:38 AM
 Leap Therapeutics, Inc. (LPTX) Receives Consensus Rating of "Buy" from Brokerages Leap Therapeutics, Inc. (LPTX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 20 at 12:18 AM
 Leap Therapeutics, Inc. (NASDAQ:LPTX) Receives Consensus Recommendation of "" from Brokerages Leap Therapeutics, Inc. (NASDAQ:LPTX) Receives Consensus Recommendation of "" from Brokerages
www.americanbankingnews.com - August 13 at 10:46 PM
Leap Therapeutics, Inc. (NASDAQ:LPTX) Posts  Earnings Results, Misses Expectations By $0.03 EPSLeap Therapeutics, Inc. (NASDAQ:LPTX) Posts Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - August 12 at 10:56 AM
Leap Therapeutics Reports Second Quarter 2017 Financial ResultsLeap Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 12 at 2:57 AM
Analysts Expect Leap Therapeutics, Inc. (LPTX) to Post ($0.50) Earnings Per ShareAnalysts Expect Leap Therapeutics, Inc. (LPTX) to Post ($0.50) Earnings Per Share
www.americanbankingnews.com - July 27 at 12:48 AM
Leap Therapeutics, Inc. (NASDAQ:LPTX) Expected to Post Earnings of -$0.50 Per ShareLeap Therapeutics, Inc. (NASDAQ:LPTX) Expected to Post Earnings of -$0.50 Per Share
www.americanbankingnews.com - July 18 at 2:45 PM
Analysts Anticipate Leap Therapeutics, Inc. (LPTX) to Announce ($0.50) Earnings Per ShareAnalysts Anticipate Leap Therapeutics, Inc. (LPTX) to Announce ($0.50) Earnings Per Share
www.americanbankingnews.com - July 10 at 8:14 PM
BRIEF-Leap Therapeutics reports qtrly net loss per share $1.39BRIEF-Leap Therapeutics reports qtrly net loss per share $1.39
www.reuters.com - May 13 at 12:01 AM
Coverage initiated on Leap Therapeutics by Ladenburg ThalmannCoverage initiated on Leap Therapeutics by Ladenburg Thalmann
us.rd.yahoo.com - March 7 at 6:06 PM

SEC Filings

Leap Therapeutics (NASDAQ:LPTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Leap Therapeutics (NASDAQ:LPTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Leap Therapeutics (NASDAQ LPTX) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.